Clinical Trial

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2024-04-22; most recent amendment 2026-03-09.
Status change: Not Yet Recruiting → Recruiting 2024-06-11
Trial Details
NCT Number NCT06384807
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions Solid Tumor
Enrollment 500 participants
Start Date 2024-04-22
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-11